Developer of medical device for treatment of benign prostatic hyperplasia. It offers minimally invasive device FloStent which consist of a nitinol stent that holds the prostatic urethra open to restore normal urinary function.
← All startups
Rivermark
Series DDeveloper of medical device for treatment of benign prostatic hyperplasia. It offers minimally invasive device FloStent which consist of a nitinol stent that holds the prostatic urethra open to restore normal urinary function.
About
Institutional investors
American Century InvestmentsVenture InvestorsTime BioVenturesView VenturesCadence Healthcare VenturesAnduril InvestorsAndera Partners
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.